Retatrutide or GLP-1 plateau: why raising the dose is not always the answer

Published 2026-10-04 · Editorial team at ZENOVA Advanced Peptide Science

Plateaus during weight reduction with GLP-1 receptor agonists and related compounds are common. A video by performance coach Nicholas Trigili argues that most stalls do not reflect an insufficient dose. Instead, he points to chronic under-eating, loss of muscle, and poor recovery, then proposes a 10-day “reset” built around more protein and carbohydrates, low-stress movement, and better sleep.

The argument identifies several important principles, but turns one possible explanation into too broad a rule. The evidence supports a more balanced conclusion: dose matters, body composition matters, and the exact 10-day sequence has not been validated in clinical trials of GLP-1 medicines or retatrutide.

What the video argues

• Plateaus usually reflect sustained energy restriction and muscle loss more than an inadequate dose.
• Increasing the dose can produce diminishing returns and more adverse effects.
• A short break from restriction, with adequate protein, carbohydrates, movement, and sleep, may improve energy and adherence.

What the evidence supports

1. Weight loss includes both fat and lean mass

In the SURMOUNT-1 body-composition substudy, tirzepatide reduced both fat mass and lean mass. About 75% of the weight lost was fat mass and 25% was lean mass in that sample. Lean mass is not identical to contractile skeletal muscle, but the finding supports monitoring protein intake, strength, and body composition instead of relying on scale weight alone.

2. Metabolic adaptation is real

Energy expenditure falls as body size decreases. Some studies also observe a reduction beyond that predicted by changes in body composition, termed adaptive thermogenesis. Its magnitude varies between people and does not mean the metabolism is “broken,” but it can narrow the effective energy deficit and slow progress.

3. Strength training and adequate nutrition deserve attention

Weight-loss trials outside the specific GLP-1 setting indicate that resistance exercise can help preserve lean mass. The evidence does not support one universal protein target for everyone; age, kidney function, body size, training, and clinical conditions affect the appropriate target.

4. A single measurement can mimic a plateau

Glycogen, sodium, hydration, gastrointestinal contents, and the menstrual cycle can change short-term scale weight. Before calling a plateau, it is more informative to examine several weeks of trend data alongside waist circumference, strength, adherence, and other relevant measures.

What is overstated or incomplete

Dose matters, but it does not explain everything

The Phase 2 retatrutide trial also reported that gastrointestinal adverse events were dose-related and were partially mitigated by a lower starting dose. The same study that demonstrates greater average weight reduction at higher doses therefore also demonstrates the importance of tolerability and titration.

A “plateau” does not always mean pharmacologic failure. It may reflect a smaller body size, altered energy expenditure, lean-mass loss, reduced spontaneous activity, insufficient sleep, stress, medication changes, inconsistent adherence, or noise in the measurement. No calculator or social-media rule can separate those causes on its own.

What do we know about the 10-day “reset”?

The individual components are plausible: a less restrictive intake may improve energy and training quality; adequate nutrition and resistance exercise may support lean-mass retention; better sleep may support adherence. However, rigid targets such as 180–200 g of protein or 200 g of carbohydrates are not universal prescriptions.

The MATADOR trial tested two-week blocks at energy balance alternating with energy restriction, not a 10-day reset during GLP-1 treatment. Its findings are interesting, but they do not prove the video’s protocol. Presenting that sequence as an established clinical solution goes beyond the evidence.

A more responsible framework for evaluating a plateau

1. Confirm a stable trend: use averages and several weeks of data, not one weigh-in.
2. Review tolerability and adherence: gastrointestinal symptoms, administration, and medication changes belong in a discussion with the treating clinician.
3. Assess composition and function: waist circumference, strength, and lean mass add context the scale cannot provide.
4. Review food intake, sleep, and activity: avoid both extreme restriction and generic online targets.
5. Consider dose only within clinical care: never change a prescribed treatment without an authorized professional.

Our metabolic profile tool can organize variables and display educational estimates, but it cannot diagnose the cause of a plateau or determine a dose.

Conclusion

The video is useful in reminding viewers that protein, strength, recovery, and excessive restriction matter. It overreaches when it treats dose as nearly irrelevant and presents a 10-day protocol as a demonstrated solution. The evidence-based position is not a choice between pharmacology and behavior: both should be evaluated with longitudinal data and appropriate supervision.

Scientific sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
2. Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.
3. Byrne NM et al. Intermittent energy restriction improves weight loss efficiency: the MATADOR study. Int J Obes. 2018.
4. Nunes CL et al. Adaptive thermogenesis after active weight loss and maintenance. Eur J Nutr. 2022.
5. Kim B et al. Resistance training during a protein-supplemented very-low-calorie diet. Clin Obes. 2018.

This article reviews selected evidence, including the 2023 phase 2 trial. It is not a comprehensive review of every later trial. Regulatory status checked on 4 October 2026: retatrutide remains investigational.